中国疟疾、肺结核、艾滋病治疗药物WHO资格预审现状

摘要/Abstract

摘要： 世界3大流行病疟疾、肺结核、艾滋病(humani mmunodeficiency virus/acquired i mmune deficien-cy syndrome，HIV/AIDS)越来越严重的危害着人类的健康。尤其是欠发达国家和地区的人民，无力承担昂贵的医疗费用，而被疾病夺去生命^[1-12]。随着流行病的快速蔓延，其防治药物市场需求迅速扩大，巨大的利润空间，聚焦了全球众多制药企业的目光。

韩文涛,张铁军. 中国疟疾、肺结核、艾滋病治疗药物WHO资格预审现状[J]. 中国防痨杂志, 2009, 31(6): 369-372.

参考文献

[1] Muturi JE, Burgess P, Novak JR. Malaria vector management: where have we come from and where are we headed[J]. Am J Trop Med Hyg, 2008, 78(4): 536-537.
[2] Na-Bangchang K, Congpuong K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand[J]. Tohoku J Exp Med, 2007, 211(2): 99-113.
[3] Sachs J, Malaney P. The economic and social burden of malaria[J]. Nature, 2002, 415(6872): 680-685.
[4] Mario C, Raviglione MD. Facing extensively drug-resistant tuberculosis-a hope and a challenge[J]. The New England J Med, 2008, 359(6): 636-638.
[5] Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa[J]. Lancet, 2006, 368(9547): 1575-1580.
[6] Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis[J]. Clin Infect Dis, 2007, 45(10): 1290-1295.
[7] World health organization. Global tuberculosis control: surveillance, planning, financing. WHO report[R]. Geneva: World health organization, 2007: 1-9.
[8] World health organization. Anti-tuberculosis drug resistance in the world, report No.4[R]. Geneva: World health organization, 2008: 11-22.
[9] 钟秋安, 仇小强. 中国广西与东南亚国家艾滋病流行及防制情况分析[J]. 现代预防医学, 2007, 34(3): 587-588.
[10] Abdel-Rahman HM, Al-karamany GS,El-Koussi NA,Youssef AF, Kiso Y. HIV protease inhibitors: peptidomimetic drugs and future perspectives[J]. Curr Med Chem, 2002, 9(21): 1905-1922.
[11] Matsushita S. Current status and future issues in the treatment of HIV-1 infection[J]. Int J Hemato, 2000, 72(1): 20-27.
[12] He N, Detels R. The HIV epidemic in China: history, response, and challenge. Cell Res, 2005, 15(11): 825-832.
[13] 周海钧. 药品注册的国际技术要求[M]. 北京: 人民卫生出版社, 2000: 2-8.
[14] 贾秀山, 廖宇静, 于飞飞, 杨燕池, 尹秋平. 黄花蒿组织培养研究[J]. 生物技术通讯, 2008, 19(2): 259-262.
[15] 胡霞, 康姗姗, 白榆. 青蒿素市场中的逆淘汰分析[J]. 中国药房, 2007, 18(6): 404-407.
[16] 于建平. 桂林南药获青蒿类药物预认证供应商质量资格[J]. 医药产业资讯, 2006, 3(1): 44-44.
[17] World health organization. Policy guidance on drug susceptibility testing of second-line antituberculosis drugs [M]. Geneva: world health organization, 2008: 4-7.
[18] Li X, Zhang Y, Shen X, Shen G, Giu X, Sun B, Mei J, Deriemer K, Small PM, Gao Q. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China[J]. J Infect Dis, 2007, 195(6): 864-873.
[19] 黄蔷, 李顺意, 徐顺清. 吡嗪酰胺抗结核杆菌作用机制的研究进展[J]. 华中医学杂志, 2006, 30(1): 72-73.
[20] Shen G, Xue Z, Shen X, Sun B, Gui X, Shen M, Mei J, Gao Q. The study recurrent tuberculosis and exogenous reinfection, Shanghai, China[J]. Emerg Infect Dis, 2006, 12(11): 1776-1778.
[21] 王巍, 金关甫. 结核病治疗药物研究新进展[J]. 传染病信息, 2003, 16(4): 159-159.
[22] 崔兆麟, 王哲, 刘国华, 郭大城, 崔为国, 薛晓玲, 孙定勇, 朱新朋, 李宁, 孙国清,郭万申. 河南省艾滋病疫情现状及流行形势分析[J]. 中国艾滋病性病, 2006, 12(4): 324-326.
[23] Laeyendecker O, Zhang GW, Quinn TC, Garten R, Ray SC, Lai S, Liu W, Chen J, Yu XF. Molecular epidemiology of HIV-1 subtypes in southern China[J]. J Acquir Immune Defic Syndr, 2005, 38(3): 356-362.
[24] 蔡步林, 李卓荣. 人类免疫缺陷病毒蛋白酶抑制剂的研究开发与展望[J].中国生化药物杂志, 2005, 26(3): 179-182.
[25] Nicole B, Michele RR. Dimerization inhibitors of HIV-1 protease[J]. Bio Chemis, 2002, 383(9): 1321-1324.
[26] 张宏艳, 钟武. 抗艾滋病药物研究进展[J]. 西南国防医药, 2004, 14(5): 565-567.
[27] 韩文涛, 张铁军. 中国原料药国际注册现状[J]. 河北工业科技, 2008, 25(3): 162-164.
[28] World health organization. Global situation of the HIV/AIDS pandemic, end 2003: Part I [M]. Weekly Epidemiological Record, 2003, 78(49): 417-423.
[29] 胡廷熹. 国际药事法规[M]. 南京: 中国药科大学出版社, 2003: 5-126.
[30] World health organization. WHO prequalification of medicine programme update for 2006[R]. Geneva: world health organization, 2007: 1-16.